You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
By employing distributed computational resources and a novel algorithm, the VariantSpark technology is able to process a trillion data points in 15 hours.
The grant will allow Weill Cornell to study genetic, social, and clinical factors that might explain why COVID-19 disproportionally affects minorities in the US.
Ten sites across the US will seek to integrate genomic risk assessment into clinical care, with a focus on diverse populations.
Working with clinical decision support vendor ActX, the suburban Chicago health system has seen strong demand for PGx and genetically informed preventive care.
Polygenic risk scores have the potential to impact cancer screening, autoimmune disease testing, and therapeutics development, but more diverse data is needed.
Functional genomics firm The DNA Company acquired digital therapeutics app My Pain Sensei, giving it an AI development platform and a Health Canada medical device license.
The informatics firm is working on an RUO COVID-19 susceptibility risk score to inform researchers and policymakers itching to restart the US economy.
The health system said that the program is encouraging patient compliance and increasing revenues and savings.
Ongoing Scripps research into polygenic risk for coronary artery disease now offers remote genetic counseling as well as an Android app.
The California health system has expanded its partnership with CancerIQ to integrate risk assessment and oncology patient management into its EHR.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.